{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:06:59Z","timestamp":1759838819125,"version":"3.40.5"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To assess differences in the quality of opioid use disorder (OUD) treatment received by Medicare beneficiaries enrolled in health plans that used prior authorization (PA) for buprenorphine\u2013naloxone compared with those enrolled in plans that did not use PA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting and Participants<\/jats:title><jats:p>Cross\u2010sectional observational study, United States. Continuously enrolled beneficiaries (71\u2009294) with an OUD who filled at least one prescription for buprenorphine\u2013naloxone between March 2012 and July 2017.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Percentage of patients tested for hepatis B, hepatis C, HIV and liver functioning; percentage of patients with urine drug screens and number of urine drug screens; continuous use of buprenorphine\u2013naloxone for at least 180\u00a0days; co\u2010use of benzodiazepines; number of outpatient visits with and without an OUD diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>PA was significantly associated with a lower likelihood of testing for hepatitis B [\u22123.5, 95% confidence interval (CI)\u00a0=\u00a0\u22124.4, \u22122.7] and C (\u22125.9, 95% CI\u00a0=\u00a0\u22126.9, \u22124.9), but the findings were inconclusive as to whether or not there was a difference in HIV (\u22121.1, 95% CI\u00a0=\u00a0\u22122.5, 0.4) or liver function testing (1.3, 95% CI\u00a0=\u00a0\u22120.1, 2.7). PA was associated with a lower likelihood of urine drug screening (\u221225.5, 95% CI\u00a0=\u00a0\u221226.8, \u221224.1) and with fewer drug screens (\u22122.5, 95% CI\u00a0=\u00a0\u22123.0, \u22122.1). Findings were inconclusive as to whether or not there was a difference in continuous use of buprenorphine\u2013naloxone (0.3, 95% CI\u00a0=\u00a0\u22121.2, 1.8). PA was associated with fewer outpatient visits (\u22122.1, 95% CI\u00a0=\u00a0\u22123.0, \u22121.2) and fewer outpatient visits with an OUD diagnosis (\u22121.7, 95% CI\u00a0=\u00a0\u22122.1, \u22121.3). PA was associated with a lower likelihood of filling benzodiazepine prescriptions before and after buprenorphine\u2013naloxone induction (\u221228.9, 95% CI\u00a0=\u00a0\u221229.6, \u221228.3) but a greater likelihood of only using benzodiazepines after buprenorphine\u2013naloxone induction (10.6, 95% CI\u00a0=\u00a09.3, 11.8).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>US Medicare patients subject to prior authorization for buprenorphine\u2013naloxone are not more likely to receive high\u2010quality treatment for opioid use disorder than patients not subject to prior authorization.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.15585","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:10:01Z","timestamp":1621948201000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The association of Medicare Part D prior authorization for buprenorphine\u2013naloxone with adherence to opioid use disorder treatment guidelines in the United States"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5697-1250","authenticated-orcid":false,"given":"William J.","family":"Parish","sequence":"first","affiliation":[{"name":"RTI International, Research Triangle Park  NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-881X","authenticated-orcid":false,"given":"Tami L.","family":"Mark","sequence":"additional","affiliation":[{"name":"RTI International  Rockville MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A.","family":"Zarkin","sequence":"additional","affiliation":[{"name":"RTI International, Research Triangle Park  NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Weber","sequence":"additional","affiliation":[{"name":"Legal Action Center  New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"unstructured":"AllenD.AHIP [internet].20202020\/06\/09\/T11:34:23+0000. Available at:https:\/\/www.ahip.org\/ahip\u2010survey\u2010prior\u2010authorization\u2010grounded\u2010in\u2010clinical\u2010evidence\u2010and\u2010selectively\u2010used\/(accessed 7 June 2021).","key":"e_1_2_8_2_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.18553\/jmcp.2017.23.8.893"},{"doi-asserted-by":"publisher","key":"e_1_2_8_4_1","DOI":"10.1001\/jamanetworkopen.2020.3132"},{"volume-title":"National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use","year":"2015","author":"American Society of Addiction Medicine","key":"e_1_2_8_5_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_6_1","DOI":"10.1097\/ADM.0000000000000633"},{"unstructured":"Centers for Medicare and Medicaid Services.CMS Measure Inventory Tool internet].2020. Available at:https:\/\/cmit.cms.gov\/CMIT_public\/ListMeasures?q=opioidsfiles\/62\/ListMeasures.html","key":"e_1_2_8_7_1"},{"volume-title":"Quality ID #468 (NQF 3175): Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)\u2014National Quality Strategy Domain: Effective Clinical Care","year":"2019","author":"MIPS Clinical Quality Measures (CQMS)","key":"e_1_2_8_8_1"},{"unstructured":"CubanskiJ. NeumanT. DamicoA.Kaiser Family Foundation [internet]. 2019. Available at:https:\/\/www.kff.org\/medicare\/issue\u2010brief\/how\u2010many\u2010medicare\u2010part\u2010d\u2010enrollees\u2010had\u2010high\u2010out\u2010of\u2010pocket\u2010drug\u2010costs\u2010in\u20102017\/(accessed 7 June 2021).","key":"e_1_2_8_9_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1080\/08897077.2014.991469"},{"doi-asserted-by":"publisher","key":"e_1_2_8_11_1","DOI":"10.1016\/j.jsat.2020.108062"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.1097\/00005650-199801000-00004"},{"volume-title":"Stata Statistical Software: Release 16","year":"2019","author":"StataCorp","key":"e_1_2_8_13_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_14_1","DOI":"10.1097\/ADM.0000000000000323"},{"unstructured":"Office of Inspector General.Medicare Improperly Paid Providers for Specimen Validity Tests Billed in Combination with Urine Drug Tests. Washington DC: Office of2018.","key":"e_1_2_8_15_1"},{"volume-title":"National Survey of Substance Abuse Treatment Services (N\u2010SSATS): 2019, Data on Substance Abuse Treatment Facilities|CBHSQ Data","year":"2020","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","key":"e_1_2_8_16_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.2105\/AJPH.2017.304132"},{"unstructured":"Centers for Disease Control and Prevention.Testing recommendations for hepatitis C virus infection [internet]. 2020 [updated 2020\/07\/29\/T01:07:01Z. Available at:https:\/\/www.cdc.gov\/hepatitis\/hcv\/guidelinesc.htm(accessed 7 June 2021).","key":"e_1_2_8_18_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1093\/infdis\/jiaa017"},{"unstructured":"National Alliance for HIV Education Workforce Development.Ending the HIV and HCV epidemics: A critical role for substance use providers.2019. Available at:https:\/\/aidsetc.org\/resource\/ending-hiv-hcv-epidemics-critical-role-substance-use-providers?ct=t%28AETC+NCRC+Monthly+Update+November+2019%29 (accessed 7 June 2021).","key":"e_1_2_8_20_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.3390\/pharmacy8010025"},{"doi-asserted-by":"publisher","key":"e_1_2_8_22_1","DOI":"10.21037\/apm.2019.12.09"},{"doi-asserted-by":"publisher","key":"e_1_2_8_23_1","DOI":"10.1001\/jamanetworkopen.2020.28557"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.1111\/add.14886"},{"unstructured":"BlueCross BlueShield of Alabama.Buprenorphine and Buprenorphine\/Naloxone for Opioid Dependence Prior Authorization and Quantity Limit Criteria Program Summary. Prime Therapeutics LLC; 2017. Available at:https:\/\/providers.bcbsal.org\/portal\/documents\/10226\/299839\/Buprenorphine+and+Buprenorphine-Naloxone+for+Opioid+Dependence+Prior+Authorization+and+Quantity+Limit+Criteria+Program+Summary\/a2a4e808-be31-4a88-9036-5216a67b8ad9?version=1.6#:~:text=TheintentoftheBuprenorphineandBuprenorphineFNaloxonefor productlabelingandForclinicalguidelinesandForclinicalstudies (accessed 7 June 2021).","key":"e_1_2_8_25_1"},{"unstructured":"Caremark.Buprenorphine Naloxone Policy. Available at:https:\/\/www.caremark.com\/portal\/asset\/Specialty_Assurant_Zubsolv.pdf(accessed 7 June 2021).","key":"e_1_2_8_26_1"},{"unstructured":"American Medical Association.Prior authorization [Internet]. n.d. Available at:https:\/\/www.ama\u2010assn.org\/amaone\/prior\u2010authorization(accessed 7 June 2021).","key":"e_1_2_8_27_1"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15585","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15585","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T20:14:12Z","timestamp":1692994452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1111\/add.15585"],"URL":"https:\/\/doi.org\/10.1111\/add.15585","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"type":"print","value":"0965-2140"},{"type":"electronic","value":"1360-0443"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"2020-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}